Aperio Group LLC grew its position in shares of LivaNova PLC (NASDAQ:LIVN) by 14.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 13,290 shares of the company’s stock after purchasing an additional 1,645 shares during the period. Aperio Group LLC’s holdings in LivaNova were worth $1,648,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. grace capital acquired a new position in shares of LivaNova during the 2nd quarter valued at $100,000. Envestnet Asset Management Inc. increased its position in shares of LivaNova by 1,054.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 1,662 shares of the company’s stock valued at $166,000 after purchasing an additional 1,518 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of LivaNova during the 1st quarter valued at $174,000. Cerebellum GP LLC acquired a new position in shares of LivaNova during the 3rd quarter valued at $191,000. Finally, Gideon Capital Advisors Inc. acquired a new position in shares of LivaNova during the 2nd quarter valued at $218,000. Institutional investors own 87.38% of the company’s stock.

Shares of NASDAQ LIVN opened at $118.81 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.21 and a current ratio of 1.65. The firm has a market capitalization of $5.97 billion, a P/E ratio of 35.89, a P/E/G ratio of 3.68 and a beta of 0.94. LivaNova PLC has a 52-week low of $76.14 and a 52-week high of $131.54.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, October 31st. The company reported $0.82 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.08). The company had revenue of $272.10 million during the quarter, compared to analyst estimates of $275.03 million. LivaNova had a positive return on equity of 8.77% and a negative net margin of 8.31%. The business’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.83 earnings per share. As a group, research analysts expect that LivaNova PLC will post 3.1 EPS for the current fiscal year.

LIVN has been the topic of several research analyst reports. BidaskClub cut LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 18th. Stifel Nicolaus lifted their price target on LivaNova from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, September 17th. Needham & Company LLC reiterated a “buy” rating and set a $135.00 price target (up from $128.00) on shares of LivaNova in a research report on Wednesday, August 1st. Jefferies Financial Group lifted their target price on LivaNova to $150.00 and gave the stock a “buy” rating in a report on Tuesday, October 2nd. Finally, Zacks Investment Research cut LivaNova from a “buy” rating to a “hold” rating in a report on Thursday, September 20th. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $126.50.

In related news, insider David S. Wise sold 1,500 shares of LivaNova stock in a transaction on Monday, October 15th. The stock was sold at an average price of $112.83, for a total value of $169,245.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Hugh M. Morrison sold 1,000 shares of LivaNova stock in a transaction on Monday, November 5th. The stock was sold at an average price of $115.65, for a total value of $115,650.00. The disclosure for this sale can be found here. Insiders sold a total of 9,058 shares of company stock worth $1,078,683 over the last 90 days. Insiders own 0.41% of the company’s stock.

WARNING: This piece was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://theolympiareport.com/2018/11/11/aperio-group-llc-has-1-65-million-position-in-livanova-plc-livn.html.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Further Reading: Do You Need a Fiduciary?

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.